Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
This study has been completed.
Study NCT00051597 Information provided by Seattle Genetics, Inc.
First Received: January 13, 2003 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hodgkin Disease
Lymphoma, Large-Cell
Sarcoma, Kaposi
Lymphoma, T-Cell, Cutaneous
Lymphoma, B-Cell
Additional conditions recognized in this trial
Hematologic Neoplasms
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell
More general conditions related to this trial
DNA Virus Infections
Hematologic Diseases
Herpesviridae Infections
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Vascular Tissue
Sarcoma
Virus Diseases
Interventions listed in this trial
SGN-30 (monoclonal antibody)
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Seattle Genetics, Inc.
Back to top of Main Content
